Market Research

Global HIV Drugs Market Report and Forecast 2023-2031

Best Price Guarantee Length Publisher Published Date SKU
from $5,999 160 Pages Expert Market Research May, 2023 EMAR17955196
Best Price Guarantee
Price from $5,999
Length 160 Pages
Publisher Expert Market Research
Published Date May, 2023
SKU EMAR17955196

Global HIV Drugs Market Report and Forecast 2023-2031


Global HIV Drugs Market Outlook


The global HIV drugs market value was USD 32.1 billion in 2022, driven by the increasing prevalence of HIV across the globe. The market size is anticipated to grow at a CAGR of 4.5% during the forecast period of 2023-2031 to achieve a value of USD 47.8 billion by 2031.

HIV Drugs: Introduction


Human Immunodeficiency Virus (HIV) continues to be a significant global public health issue, affecting millions of people worldwide. HIV drugs, specifically antiretroviral therapy (ART), have played a crucial role in managing the disease and improving the quality of life for those living with HIV. ART involves the use of a combination of drugs that work together to suppress the virus, prevent its progression to Acquired Immune Deficiency Syndrome (AIDS), and reduce the risk of transmission.

HIV Drugs Market Scenario


In recent years, the global HIV drugs market has witnessed considerable growth, driven by factors such as the increasing prevalence of HIV, advancements in antiretroviral therapy, the development of novel treatment regimens, and a growing focus on expanding access to treatment in low- and middle-income countries. The market is also fuelled by the rising demand for innovative therapies that offer improved efficacy, fewer side effects, and better patient adherence compared to traditional treatments.

The adoption of HIV drugs has been increasing steadily as the prevalence of HIV remains high, and advancements in antiretroviral therapy led to the development of more effective and tolerable treatments. The increasing focus on expanding access to treatment in low- and middle-income countries has further fuelled the growth of the market, as these regions account for a significant proportion of the global HIV burden.

HIV Drugs Market Segmentations


Market Breakup by Drug Class
  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Drugs
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors
  • Others
Market Breakup by Route of Administration
  • Oral
  • Tablets
  • Capsules
  • Parenteral
  • Intravascular
  • intramuscular
  • Others
Market Breakup by Drug Type
  • Branded
  • Generics
Market Breakup by End User
  • Hospitals
  • Clinics
  • Specialty Centers
  • Research Institutes
  • Others
Market Breakup by Distribution Channels
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the HIV Drugs Market

  • New antiretroviral drugs and regimens: The development of novel antiretroviral drugs and treatment regimens has improved treatment outcomes and reduced side effects, leading to better patient adherence and overall quality of life.
  • Long-acting injectable therapies: The emergence of long-acting injectable HIV therapies has the potential to revolutionize treatment by reducing the burden of daily oral medication and improving treatment adherence.
  • Expanding access to treatment: Global efforts to increase access to antiretroviral therapy in low- and middle-income countries have contributed to the growth of the HIV drugs market.
  • Drug resistance and treatment optimization: Ongoing research focuses on addressing the issue of drug resistance, as well as optimizing treatment regimens to minimize side effects and maximize efficacy.
  • Prevention strategies: The market is also witnessing growth in the demand for pre-exposure prophylaxis (PrEP) drugs, which are used to prevent HIV infection in high-risk individuals.

HIV Drugs Market: Competitor Landscape


The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • GSK plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Mylan N.V.
  • Sanofi
  • Bayer AG
  • ViiV Healthcare group of companies
  • Genentech, Inc
*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 HIV/AIDS Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 HIV/AIDS Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America HIV Epidemiology (2016-2031)
5.3 Europe HIV Epidemiology (2016-2031)
5.4 Asia-Pacific HIV Epidemiology (2016-2031)
5.5 Latin America HIV Epidemiology (2016-2031)
5.6 Middle East & Africa HIV Epidemiology (2016-2031)
6 Global HIV Drugs Market Overview
6.1 Global HIV Drugs Market Historical Value (2016-2022)
6.2 Global HIV Drugs Market Forecast Value (2023-2031)
7 Global HIV Drugs Market Landscape
7.1 Global HIV Drugs Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global HIV Drugs Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by End User
7.2.3 Analysis by Distribution Channel
8 Cost of Treatment
9 Global HIV Drugs Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Global HIV Drugs Market Segmentation
10.1 Global HIV Drugs Market by Drug Class
10.1.1 Market Overview
10.1.2 Nucleoside Reverse Transcriptase Inhibitors
10.1.3 Multi-Class Combination Drugs
10.1.4 Protease Inhibitors
10.1.5 HIV Integrase Strand Transfer Inhibitors
10.1.6 Non-Nucleoside Reverse Transcriptase Inhibitors
10.1.7 Entry Inhibitors - CCR5 Co-Receptor Antagonist
10.1.8 Fusion Inhibitors
10.1.9 Others
10.2 Global HIV Drugs Market by Route of Administration
10.2.1 Market Overview
10.2.2 Oral
10.2.2.1 Tablets
10.2.2.2 Capsules
10.2.3 Parenteral
10.2.3.1 Intravascular
10.2.3.2 intramuscular
10.2.3.3 Others
10.3 Global HIV Drugs Market by Drug Type
10.3.1 Market Overview
10.3.2 Branded
10.3.3 Generics
10.4 Global HIV Drugs Market by End User
10.4.1 Market Overview
10.4.2 Hospitals
10.4.3 Clinics
10.4.4 Specialty Centers
10.4.5 Research Institutes
10.4.6 Others
10.5 Global HIV Drugs Market by Distribution Channels
10.5.1 Market Overview
10.5.2 Hospitals Pharmacies
10.5.3 Retail Pharmacies
10.5.4 Online Pharmacies
10.5.5 Others
10.6 Global HIV Drugs Market by Region
10.6.1 Market Overview
10.6.2 North America
10.6.3 Europe
10.6.4 Asia Pacific
10.6.5 Latin America
10.6.6 Middle East and Africa
11 North America HIV Drugs Market
11.1 Market Share by Country
11.2 United States of America
11.3 Canada
12 Europe HIV Drugs Market
12.1 Market Share by Country
12.2 United Kingdom
12.3 Germany
12.4 France
12.5 Italy
12.6 Others
13 Asia Pacific HIV Drugs Market
13.1 Market Share by Country
13.2 China
13.3 Japan
13.4 India
13.5 ASEAN
13.6 Australia
13.7 Others
14 Latin America HIV Drugs Market
14.1 Market Share by Country
14.2 Brazil
14.3 Argentina
14.4 Mexico
14.5 Others
15 Middle East and Africa HIV Drugs Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.3 United Arab Emirates
15.4 Nigeria
15.5 South Africa
15.6 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by Year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Regulatory Framework
21.1 Regulatory Overview
21.1.1 US FDA
21.1.2 EU EMA
21.1.3 INDIA CDSCO
21.1.4 JAPAN PMDA
21.1.5 Others
22 Supplier Landscape
22.1 F. Hoffmann-La Roche Ltd.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Bristol-Myers Squibb Company
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 AstraZeneca
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 GSK plc
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Merck & Co., Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Novartis AG
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Pfizer Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Sun Pharmaceutical Industries Ltd
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Mylan N.V.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Sanofi
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Bayer AG
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 ViiV Healthcare group of companies
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Genentech, Inc
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
23 Global HIV Drugs Market-Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket

$5,999
$9,999

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings